Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes

被引:180
作者
Hurt, A. C.
Selleck, P.
Komadina, N.
Shaw, R.
Brown, L.
Barr, I. G.
机构
[1] WHO, Collaborating Ctr Reference & Res Influenza, Parkville, Vic 3052, Australia
[2] Monash Univ, Sch Appl Sci, Churchill, Vic 3842, Australia
[3] CSIRO, Australian Anim Hlth Lab, Geelong, Vic 3220, Australia
[4] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia
基金
英国医学研究理事会;
关键词
influenza; A(H5N1); NA inhibitors; adamantanes; drug resistance;
D O I
10.1016/j.antiviral.2006.10.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Since 2003, highly pathogenic A(H5N]) influenza viruses have been the cause of large-scale death in poultry and the subsequent infection and death of over 140 humans. A group of 55 influenza A(H5N]) viruses isolated from various regions of South East Asia between 2004 and 2006 were tested for their susceptibility to the anti-influenza drugs the neuraminidase inhibitors and adamantanes. The majority of strains were found to be fully sensitive to the neuraminidase inhibitors oseltamivir carboxylate, zanamivir and peramivir; however two strains demonstrated increased IC50 values. Sequence analysis of these strains revealed mutations in the normally highly conserved residues 116 and 117 of the NI neuraminidase. Sequence analysis of the M2 gene showed that all of the A(H5N 1) viruses from Vietnam, Malaysia and Cambodia contained mutations (L261 and S31N) associated with resistance to the adamantane drugs (rimantadine and amantadine), while strains from Indonesia were found to be a mix of both adamantane resistant (S31N) and sensitive viruses. None of the A(H5NI) viruses from Myanmar contained mutations known to confer adamantane resistance. These results support the use of neuraminidase inhibitors as the most appropriate class of antiviral drug to prevent or treat human A(H5NI) virus infections. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:228 / 231
页数:4
相关论文
共 18 条
[1]   Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial [J].
Bresson, Jean-Louis ;
Perronne, Christian ;
Launay, Odile ;
Gerdil, Catherine ;
Saville, Melanie ;
Wood, John ;
Hoeschler, Katja ;
Zambon, Maria C. .
LANCET, 2006, 367 (9523) :1657-1664
[2]   Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States [J].
Bright, RA ;
Shay, DK ;
Shu, B ;
Cox, NJ ;
Klimov, AI .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (08) :891-894
[3]   Distribution of amantadine-resistant H5N1 avian influenza variants in Asia [J].
Cheung, Chung-Lam ;
Rayner, Jane M. ;
Smith, Gavin J. D. ;
Wang, Pui ;
Naipospos, T. S. P. ;
Zhang, Jinxia ;
Yuen, Kwok-Yung ;
Webster, Robert G. ;
Peiris, J. S. Malik ;
Guan, Yi ;
Chen, Honglin .
JOURNAL OF INFECTIOUS DISEASES, 2006, 193 (12) :1626-1629
[4]   Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors [J].
Gubareva, LV .
VIRUS RESEARCH, 2004, 103 (1-2) :199-203
[5]   THE MOLECULAR-BASIS OF THE SPECIFIC ANTI-INFLUENZA ACTION OF AMANTADINE [J].
HAY, AJ ;
WOLSTENHOLME, AJ ;
SKEHEL, JJ ;
SMITH, MH .
EMBO JOURNAL, 1985, 4 (11) :3021-3024
[6]   Antivirals for influenza: Historical perspectives and lessons learned [J].
Hayden, Frederick G. .
ANTIVIRAL RESEARCH, 2006, 71 (2-3) :372-378
[7]   Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient [J].
Hurt, AC ;
Iannello, P ;
Jachno, K ;
Komadina, N ;
Hampson, AW ;
Barr, IG ;
McKimm-Breschkin, JL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (05) :1872-1874
[8]   Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir [J].
Hurt, AC ;
Barr, IG ;
Hartel, G ;
Hampson, AW .
ANTIVIRAL RESEARCH, 2004, 62 (01) :37-45
[9]   Resistant influenza A viruses in children treated with oseltarnivir: descriptive study [J].
Kiso, M ;
Mitamura, K ;
Sakai-Tagawa, Y ;
Shiraishi, K ;
Kawakami, C ;
Kimura, K ;
Hayden, FG ;
Sugaya, N ;
Kawaoka, Y .
LANCET, 2004, 364 (9436) :759-765
[10]   Pandemics, antiviral stockpiles and biosecurity in Australia: what about the generic option? [J].
Lokuge, B ;
Drahos, P ;
Neville, W .
MEDICAL JOURNAL OF AUSTRALIA, 2006, 184 (01) :16-20